Roche has announced robust 2025 results, reporting a 7% increase in Group sales (CER) and a massive 58% jump in IFRS net income. With 12 positive late-stage clinical readouts—including the promising obesity candidate CT-388—and a bullish 2026 forecast, the Swiss healthcare giant proves its resilience despite significant currency headwinds.
India’s Eyestem Research advances to Phase 2 clinical trials for Eyecyte-RPEâ„¢ following stellar Phase 1 results that showed significant vision restoration. As a scalable “off-the-shelf” solution for dry AMD, this therapy represents a major leap in regenerative medicine and a potential global cure for Geographic Atrophy.
Roche has unveiled breakthrough Phase II data for its obesity candidate, CT-388, showing a 22.5% reduction in body weight over 48 weeks. With nearly 73% of pre-diabetic patients returning to normal glucose levels, Roche is fast-tracking the drug into Phase III Enith trials to challenge the metabolic health market.
Samsung Biologics (KRX: 207940.KS), a world-leading contract development and manufacturing organization (CDMO), has reported record-breaking financial results for the fourth quarter and full fiscal year [Read More…]
In a landmark development for personalized medicine, Moderna, Inc. and Merck (known as MSD outside the U.S. and Canada) announced today that their investigational mRNA-based [Read More…]
Abbott concludes 2025 with double-digit earnings growth and a powerful surge in Medical Device sales. With a new 2026 organic growth forecast of 6.5%–7.5% and a major entry into cancer diagnostics via the Exact Sciences acquisition, the healthcare leader signals a year of accelerated expansion ahead.
ohnson & Johnson has concluded a ‘catapult year’ with $94.2 billion in revenue, driven by a surge in oncology sales and strategic MedTech innovations. As the healthcare giant prepares to spin off its orthopaedics business, it sets its sights on becoming the first healthcare company to surpass the $100 billion annual revenue milestone in 2026.
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156). [Read More…]
AbbVie and Genmab have announced significant topline results from the pivotal Phase 3 EPCORE® DLBCL-1 trial. The study marks a clinical milestone as the first Phase 3 trial to demonstrate a statistically significant improvement in progression-free survival (PFS) for a CD3xCD20 bispecific antibody monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Novartis reaches a historic milestone in immunology as the FDA grants Breakthrough Therapy designation to ianalumab for Sjögren’s disease. Backed by successful Phase III NEPTUNUS trials, this dual-action monoclonal antibody is poised to become the first targeted therapy for this chronic autoimmune condition. With global regulatory submissions planned for early 2026, ianalumab represents a significant leap forward for millions of patients currently facing an immense unmet medical need.
